10-K: Mountain Crest Acquisition Corp. V Faces Delisting After Business Combination Deadline Miss; Reports Financial Results

Mountain Crest Acquisition Corp. V reports its 10-K filing, highlighting a failed business combination deadline, subsequent delisting from Nasdaq, and ongoing efforts to secure a new merger target.

Summary

• Mountain Crest Acquisition Corp. V, a blank check company, filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• The company's primary focus is to identify and complete a business combination with one or more businesses.
• A previously planned business combination with AUM Biosciences Pte. Ltd. was terminated on June 8, 2023.
• The company's securities were transferred to The Nasdaq Capital Market on October 27, 2023, but were subsequently delisted on November 21, 2024, due to non-compliance with Nasdaq requirements.
• As of December 31, 2024, the company had $1,157,312 in its Trust Account.
• The company incurred a net loss of $374,454 for the year ended December 31, 2024.
• The company has entered into a Business Combination Agreement with CUBEBIO Co., Ltd., with a potential closing date no later than May 15, 2025.
• The company's ability to continue as a going concern is dependent on completing a business combination by November 16, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting, net losses, and the uncertainty surrounding the company's ability to complete a business combination and continue as a going concern.

Positives

• The company has entered into a Business Combination Agreement with CUBEBIO Co., Ltd., potentially leading to a successful merger.
• The company has a history of regaining compliance with Nasdaq listing rules after receiving deficiency notices.
• The company's management has experience in structuring complex transactions and accessing a network of relationships to identify and evaluate suitable target businesses.

Negatives

• The company failed to meet the initial business combination deadline, resulting in delisting from Nasdaq.
• The company has incurred net losses for the years ended December 31, 2024 and 2023.
• The company's ability to continue as a going concern is dependent on completing a business combination by November 16, 2025.
• The company has a history of receiving deficiency notices from Nasdaq for failing to comply with listing requirements.

Risks

• The company may not be able to complete a business combination within the required timeframe.
• The company's financial condition and results of operations may be negatively affected by the COVID-19 pandemic.
• The company may face intense competition from other entities seeking business combination targets.
• The company's reliance on its Sponsor for working capital loans may not be sufficient to fund its operations.
• The company's management may have conflicts of interest due to multiple business affiliations.

Future Outlook

The company is focused on completing a business combination with CUBEBIO Co., Ltd. by May 15, 2025, and must complete a business combination by November 16, 2025, to avoid liquidation.

Industry Context

The announcement is typical for SPACs nearing their expiration date, highlighting the pressure to find and close a deal or face liquidation. The delisting from Nasdaq adds further urgency to the situation.

Comparison to Industry Standards

• Given the company's small size and lack of revenue, comparing it to industry giants is not relevant.
• A more appropriate comparison would be to other SPACs in a similar stage of their lifecycle, particularly those facing imminent deadlines for completing a business combination.
• Comparable companies include other SPACs that have struggled to find suitable targets and have faced delisting or liquidation.
• The success rate of SPACs in completing mergers has varied widely, with many failing to deliver expected returns to investors.

Related Party Transactions

• The company has entered into various related party transactions with its Sponsor, including promissory notes and an administrative support agreement.

Stakeholder Impact

• Shareholders face the risk of liquidation if the company fails to complete a business combination.
• Employees of the target company may be affected by the terms of the business combination.
• Creditors of the company may be affected by the company's ability to repay its debts.

Next Steps

• The company must seek stockholder approval for the business combination with CUBEBIO Co., Ltd.
• The company must complete the business combination with CUBEBIO Co., Ltd. by May 15, 2025.
• The company must regain compliance with Nasdaq listing rules or find an alternative exchange for its securities.

Key Dates

Keywords

business combination, SPAC, delisting, CUBEBIO, Mountain Crest Acquisition Corp. V, merger, Nasdaq, financial results, going concern, AUM Biosciences